MyCardium AI

AI-based heart measurement lab service.

hologram body with heart

MyCardium was founded in 2022 by Professors' James Moon, Mark Westwood, Charlotte Manisty and others. 

Its mission is to eliminate uncertainty and delay in cardiovascular diagnosis, by equipping clinicians with accurate, AI-powered insights that can identify heart conditions earlier, reduce errors, and improve patient outcomes, so every patient receives the right care at the right time. 

The spinout developed ‘superhuman AI’ for interpreting heart scans / echocardiographs with human-in-the-loop AI assessment of over 100 different measurements of cardiac structures such as the chambers, valves, vessels, and pericardium.

MyCardium was set up through UCL Ventures’ Portico Ventures, which helps UCL researchers set up technology-based businesses that can thrive in a fast-moving ecosystem, by providing spinout companies with an exclusive and royalty-free licence in return for a fixed percentage of equity (company ownership).

The MyCardium AI journey so far:

  • 2022: company registered in Liverpool
  • 2023: MyCardium AI receives the Liverpool City Region 'Official Tech Climber 2023' award
  • 2024: the spinout is awarded ISO 27001 certification by BSI
  • 2025: 
    • MyCardium AI Secures ISO 13485 Accreditation: Setting New Standards in Medical Device Quality
    • MyCardium AI is recognised as one of the UK’s top 16 AI start-ups to watch by Sifted.

Team

Professor James Moon

CEO

Professor Moon's research focuses on understanding rare and common heart conditions and pioneers advanced diagnostic techniques with therapeutic solutions to improve patient outcomes.

Professor Charlotte Mainsty

Co-founder and Director

Professor Mainsty is a Professor of Cardiology at UCL, specialising in cardiac MRI, and is clinical lead for Cardio-Oncology at Barts Heart Centre.

Professor Mark Westwood, Co-founder and Director

David Philips

Senior Business Manager

David is a molecular geneticist and virologist by background and has worked managing and licensing intellectual property for over 20 years.

He has twice worked for the University of Oxford’s technology transfer office, where he was involved in technologies as diverse as novel anti-cancer agents and software for medical imaging and scanning. He has also spent considerable time in industry, working for multinationals such as GlaxoSmithKline and Mercury Pharma, through to small university-based start-up companies.

David is responsible for commercialisation opportunities arising from the Institute of Child Health at Great Ormond Street Hospital, the UCL Cancer Institute and the Institute of Cardiovascular Science.